Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Market Intelligence Manager||
Olympus Corporation of the Americas
Food and Drug Administration
|Silver Spring, MD|
|Pharmacy Care Manager||
National Association of Chain Drug Stores
|Vice President, Commercial Markets||
|Health Plan CEO – Oregon||
Trillium Community Health Plan